| Reinaldo J Sanchez-torres, MD | |
|
611 W. Park St., Cardiology, Urbana, IL 61801-2500 | |
| (217) 904-7000 | |
| (217) 904-7742 |
| Full Name | Reinaldo J Sanchez-torres |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 25 Years |
| Location | 611 W. Park St., Urbana, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467468553 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 036115895 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Carle Foundation Hospital | Urbana, IL | Hospital |
| Carle Hoopeston Regional Health Center | Hoopeston, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hoopeston Community Memorial Hospital | 3577456037 | 121 |
| Carle Health Care Incorporated | 3577515774 | 808 |
News Archive
Now, armed with a deeper understanding of full facial contouring, dermatologists are using soft-tissue fillers to enhance and restore volume loss in the cheek area, thereby smoothing nasolabial folds (the wrinkles that form along the bottom of the nose to the corners of the mouth). In addition, newly introduced fractional radiofrequency technology to address skin laxity is showing promise by stimulating collagen contraction and reducing loose skin in the lower-face.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions, including Boston University School of Public Health, to explore potential links between COVID-19 vaccination and menstrual changes.
Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).
› Verified 9 days ago
| Entity Name | Hoopeston Community Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366480873 PECOS PAC ID: 3577456037 Enrollment ID: O20040210000011 |
News Archive
Now, armed with a deeper understanding of full facial contouring, dermatologists are using soft-tissue fillers to enhance and restore volume loss in the cheek area, thereby smoothing nasolabial folds (the wrinkles that form along the bottom of the nose to the corners of the mouth). In addition, newly introduced fractional radiofrequency technology to address skin laxity is showing promise by stimulating collagen contraction and reducing loose skin in the lower-face.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions, including Boston University School of Public Health, to explore potential links between COVID-19 vaccination and menstrual changes.
Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).
› Verified 9 days ago
| Entity Name | Richland Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467492124 PECOS PAC ID: 3870565732 Enrollment ID: O20040811000131 |
News Archive
Now, armed with a deeper understanding of full facial contouring, dermatologists are using soft-tissue fillers to enhance and restore volume loss in the cheek area, thereby smoothing nasolabial folds (the wrinkles that form along the bottom of the nose to the corners of the mouth). In addition, newly introduced fractional radiofrequency technology to address skin laxity is showing promise by stimulating collagen contraction and reducing loose skin in the lower-face.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions, including Boston University School of Public Health, to explore potential links between COVID-19 vaccination and menstrual changes.
Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).
› Verified 9 days ago
| Entity Name | Kirby Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386635373 PECOS PAC ID: 6901791144 Enrollment ID: O20050801000320 |
News Archive
Now, armed with a deeper understanding of full facial contouring, dermatologists are using soft-tissue fillers to enhance and restore volume loss in the cheek area, thereby smoothing nasolabial folds (the wrinkles that form along the bottom of the nose to the corners of the mouth). In addition, newly introduced fractional radiofrequency technology to address skin laxity is showing promise by stimulating collagen contraction and reducing loose skin in the lower-face.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions, including Boston University School of Public Health, to explore potential links between COVID-19 vaccination and menstrual changes.
Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).
› Verified 9 days ago
| Entity Name | Carle Health Care Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154653947 PECOS PAC ID: 3577515774 Enrollment ID: O20100513000829 |
News Archive
Now, armed with a deeper understanding of full facial contouring, dermatologists are using soft-tissue fillers to enhance and restore volume loss in the cheek area, thereby smoothing nasolabial folds (the wrinkles that form along the bottom of the nose to the corners of the mouth). In addition, newly introduced fractional radiofrequency technology to address skin laxity is showing promise by stimulating collagen contraction and reducing loose skin in the lower-face.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions, including Boston University School of Public Health, to explore potential links between COVID-19 vaccination and menstrual changes.
Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Reinaldo J Sanchez-torres, MD 611 W. Park St., Bwpc, Urbana, IL 61801-2500 Ph: (217) 383-6792 | Reinaldo J Sanchez-torres, MD 611 W. Park St., Cardiology, Urbana, IL 61801-2500 Ph: (217) 904-7000 |
News Archive
Now, armed with a deeper understanding of full facial contouring, dermatologists are using soft-tissue fillers to enhance and restore volume loss in the cheek area, thereby smoothing nasolabial folds (the wrinkles that form along the bottom of the nose to the corners of the mouth). In addition, newly introduced fractional radiofrequency technology to address skin laxity is showing promise by stimulating collagen contraction and reducing loose skin in the lower-face.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions, including Boston University School of Public Health, to explore potential links between COVID-19 vaccination and menstrual changes.
Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).
› Verified 9 days ago
Joselyn Joseph, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 W. Park St., Hospitalist, Urbana, IL 61801 Phone: 217-383-3129 Fax: 217-326-1550 | |
Dr. Uday Bhaskar Kanakadandi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 W Park St, Hvi, Urbana, IL 61801 Phone: 217-383-3110 | |
Dr. Nelson Onyekachukwu Okobia, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 611 W Park St, Urbana, IL 61801 Phone: 217-549-6585 | |
Robert W. Kirby, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 602 W University Ave, Urbana, IL 61801 Phone: 217-383-3311 | |
Pardeep Kumar Thourani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 W Park St, Carle Forum, Ll, Urbana, IL 61801 Phone: 217-383-3110 | |
Benjamin J Rhee, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 W. Park St., Cardiology, Urbana, IL 61801 Phone: 217-904-7000 Fax: 217-904-7742 | |
Mr. Mobeen Zaka Haider, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 611 W. Park St. Carle Foundation Hospital, Urbana, IL 61801 Phone: 217-383-3310 |